Saphetor develops software and analytical processes that perform clinically meaningful genome‑scale analysis based on Next Generation Sequencing (NGS). Its core product is a decision‑support platform that combines data integration, annotation, and interpretation in an intuitive interface for clinicians and researchers. The company uses proprietary algorithms and trade‑secret know‑how and has aggregated 20 leading databases representing more than 10 billion genetic variant annotations. Saphetor’s services target large gene panels, exomes, and whole genomes to help clinicians make faster, more accurate diagnoses and select therapies, particularly for cancer and hard‑to‑diagnose conditions such as rare diseases and cognitive impairment. The company said the proceeds from its recent financing will be used to further develop advanced NGS analysis capabilities and to expand its commercial and research collaborations in Europe and beyond into 2017. Saphetor was founded in 2014 and is based in Lausanne, Switzerland.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2016